Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
Date:2/22/2008

was primarily attributable to a $7,839,000 increase in research and development expenses related to the Company's Sulonex pivotal Phase 3 and Phase 4 clinical program, a $6,702,000 increase in expenses related to KRX-0401 (perifosine), a $3,294,000 increase in expenses related to Zerenex (ferric citrate) and a $1,580,000 increase in expenses related to the Company's other clinical compounds. The increase in net loss was also due to a $1,838,000 decrease in interest and other income. The increase in net loss was partially offset by a $4,252,000 decrease in non- cash compensation expense related to stock option and restricted stock grants.

Commenting on the year and the quarter, Michael S. Weiss, Keryx's Chairman and Chief Executive Officer, said, "This was an important year for the Company as we made substantial progress toward the potential commercialization of Sulonex, including: completion of the active treatment portion of the SUN- MICRO Phase 3 trial with the subsequent completion of the trial in February 2008; enrollment of over 50% of the patients required for completion of the SUN-MACRO Phase 4 trial; completion of four Independent Data Safety Monitoring Committee (DSMC) meetings surrounding the Phase 3 and Phase 4 trials culminating in the fourth quarter DSMC final review of the safety and efficacy data related to the Sulonex Phase 3 trial, at which time the DSMC again found no cogent reason to recommend that we alter or terminate the study; and the completion of our first commercial-scale manufacturing facility with final validation anticipated in 2008." Mr. Weiss, continued, "With the Phase 3 trial now complete, we anxiously await the final results from the study, and continue to target making an announcement of the top line data before the end of next month. In preparation for the potential commercial launch of Sulonex, we continue to build our internal expertise, including key hires in commercial, medical affairs, quality operations, legal and ac
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
2. Keryx Biopharmaceuticals Announces Additions to Management Team
3. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
4. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
7. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
8. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
9. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
10. Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2007 Earnings Release Conference Call Webcast
11. Genta Announces Senior Management Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... ST. LOUIS , Sept. 18, 2014 /PRNewswire/ ... ) announced today it has entered into a ... Michigan (U-M) Medical School,s Vector Core. Under the ... Sigma CRISPR technology, experimental design consultation, and dedicated ... poised to accelerate gene editing-based research at the ...
(Date:9/18/2014)... loss and diabetes prevention, could actually hasten the development ... it in a surprising way: by changing the composition ... population of bacteria residing in our intestines. These findings, ... published today in Nature . Among other things, ... Department, who led this research together with Prof. Eran ...
(Date:9/18/2014)... CA (PRWEB) September 18, 2014 ... which include Sartorius/Biohit, Socorex, Capp, and AccuPet brand ... volumes of 100 uL or less and are ... and forensic applications. , The micropipette promotions ... quality and economic alternative products to help customers ...
(Date:9/17/2014)... Sept. 17, 2014 The global consumption of squalene ... Squalene is a natural skin-identical chemical that finds applications in ... food supplements, pharmaceuticals, and in other applications like high grade ... has a few major players and is regionally segregated. Sophim ... Liver Oil Co. Ltd. ( Japan ), SeaDragon ...
Breaking Biology Technology:Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4Gut bacteria, artificial sweeteners and glucose intolerance 2Gut bacteria, artificial sweeteners and glucose intolerance 3Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 2Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 3Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 2Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 3
... generation design reduces the amount of retraction needed for surgical ... ... 23 Pioneer Surgical Technology,today announces the market availability of the ... cervical fusion procedures while addressing the clinical needs of,anterior cervical discectomy ...
... Technology,Inc. (Nasdaq: EFUT ) (,eFuture,), a leading ... to China,s retail and consumer goods,industries, today announced ... its,mySHOP Retail Business Management System 3.0 (,mySHOP 3.0, ... Group,). eFuture will install,the system at Tiens Group,s ...
... company enters into a strategic supply chain agreement in preparation for ... ... July 23, 2008 -- CN Probes , an emerging nanotech ... (contract manufacturer). This agreement puts CN Probes closer to ramping up ...
Cached Biology Technology:Pioneer(R) Surgical Technology, Inc. Announces the Market Launch of the SlimFuse(TM) Anterior Cervical Plate System 2eFuture Signs Contract to Provide Tiens Group with Retail Business Management System 2eFuture Signs Contract to Provide Tiens Group with Retail Business Management System 3eFuture Signs Contract to Provide Tiens Group with Retail Business Management System 4eFuture Signs Contract to Provide Tiens Group with Retail Business Management System 5Carbon Nanoprobes, Inc Announces Production Agreement With Leading MEMS Foundry 2Carbon Nanoprobes, Inc Announces Production Agreement With Leading MEMS Foundry 3
(Date:9/17/2014)... September 17, 2014 Researchers at UTSouthwestern Medical Center ... circulating protein apolipoprotein E, called apoE3, helps repair the ... apoE4, do not get the benefit of this repair, ... "We believe that we have identified one mechanism by ... a genetic variant, apoE4, is detrimental," said Dr. ...
(Date:9/17/2014)... University] After decades of decline, grasses have returned ... the eye, the marsh in those places seems healthy ... key service of the marsh coastal protection ... the ecosystem function hasn,t come back," said ecologist Mark ... of the study in the journal Biological Conservation ...
(Date:9/17/2014)... the United Kingdom forms a new crime unit designed ... uproar last year over horse meat being passed off ... technique for detecting meat adulteration. They describe their approach, ... ACS, Journal of Agricultural and Food Chemistry . ... is a major global economic problem. But they also ...
Breaking Biology News(10 mins):Protein variant may boost cardiovascular risk by hindering blood vessel repair 2Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3
... issue of the Journal of General Physiology ... of British Columbia, Vancouver) and colleagues that explores pore ... in vivo nonsense suppression technology. The study will be ... to Riccardo Olcese (UCLA) in a commentary accompanying the ...
... in DNA sequencing make determining how living things ... which their genes have been rearranged on chromosomes. ... requires massive computing impossible even on the most ... $1 million project, funded by the National Science ...
... in high-throughput DNA sequencing have opened up the ... by analyzing the ways in which their genes ... evolutionary relationships from rearrangement events is computationally intensive ... today. Research recently funded by the American ...
Cached Biology News:Petascale computational tools could revolutionize understanding of genomic evolution 2Petascale computing tools could provide deeper insight into genomic evolution 2Petascale computing tools could provide deeper insight into genomic evolution 3
... Normal;heading 1;heading ... types and experimental ... for standard transfection ... transduction systems. ViraPower ...
... Product Rabbit polyclonal to ... conjugated to KLH, corresponding to amino ... / Specificity Cross-reacts with Rat.Expected to ... Mouse (100% identity with immunogen), Rabbit (100% ...
RayBio Human Angiogenesis Antibody Array 2.1 (8 array membranes) with Accessory, detects 23 angiogenic factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
... Inventory Racks for cryogenic vials. ... cardboard or stainless steel boxes ... cryo vials. Vapor phase ... Platform risers to be ...
Biology Products: